Harvest Pharmaceuticals

Harvest Pharmaceuticals was a specialty pharmaceutical company dedicated to the development of therapies for rare and orphan diseases. The company is best known for developing Cystaran (cysteamine ophthalmic solution), which received FDA approval in 2012 as the first treatment for corneal cystine crystals in patients with cystinosis. Shortly after this regulatory milestone, Harvest Pharmaceuticals was acquired by Sigma-Tau Pharmaceuticals, which is now known as Leadiant Biosciences. The company's work significantly improved the standard of care for individuals suffering from the ocular manifestations of nephropathic cystinosis. Harvest focused on identifying and developing products that addressed significant unmet medical needs within niche patient populations. Its successful commercialization of an orphan drug highlighted its expertise in navigating the complex regulatory pathways associated with rare diseases.